Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 41Genitourinary 20Other hematologic neoplasm 14Thoracic 1Plasma cell 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 46Lenalidomide 27daratumumab 24Bortezomib 23pomalidomide 22Specimen Handling 16Cyclophosphamide 16Biopsy 16carfilzomib 14Magnetic Resonance Spectroscopy 13Calcium Dobesilate 12talquetamab 10iberdomide 10fludarabine 9Melphalan 9isatuximab 8belantamab mafodotin 8selinexor 6dexamethasone acetate 6dexamethasone 21-phosphate 6auricularum 6X-Rays 6fludarabine phosphate 5elotuzumab 4Whole-Body Irradiation 4Nuclear Medicine Department, Hospital 4trametinib 3tocilizumab 3dabrafenib 3Thalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prednisone × Plasma cell × 30 days × Clear all
NCT00602641 2026-05-29

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
306 enrolled 12 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡